Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Dec 24

PMID 34943600

Citations 4

Authors

Xiaoqing Li

Lan Sun

Andres Stucky

Lingli Tu

Jin Cai

Xuelian Chen

Zhongjun Wu

Xuhong Jiang

Shengwen Calvin Li

Affiliations

Soon will be listed here.

Abstract

Background: Neuroblastoma (N.B.) is the most common tumor in children. The gene (B Double Prime 1) plays a role in cancers but is less known in N.B. Thus, we conducted this study to investigate the value of mutations in N.B.

Prognosis:

Methods: A dataset of 121 NB patients from the Cancer Genome Atlas database was used to analyze gene mutations by RNA sequencing. Kaplan-Meier estimates were performed for overall survival (O.S.) analysis on variants, and Cox's proportional hazards regression model was used for multivariate analysis.

Results: In 121 NB patients, we identified two variants of associated with N.B., located at chr5:71511131 and chr5:71510884. The prevalence of these variants, I1264M and V1347M, was 52.9% (64/121) and 45.5% (55/121), respectively. O.S. analysis showed a significant difference between subgroups with or without variants ( < 0.05). Multivariate analysis further revealed that ariants were independent prognostic variables in N.B. ( < 0.05).

Conclusion: Our results suggest variants are associated with significantly improved clinical outcomes in N.B., thus providing clinicians with a new tool.

Citing Articles

Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

Lozano-Montoya J, Jimenez-Pastor A, Fuster-Matanzo A, Weiss G, Cerda-Alberich L, Veiga-Canuto D Front Oncol. 2025; 15:1528836.

PMID: 40061893 PMC: 11886962. DOI: 10.3389/fonc.2025.1528836.

BDP1 as a biomarker in serous ovarian cancer.

Cabarcas-Petroski S, Olshefsky G, Schramm L Cancer Med. 2022; 12(5):6401-6418.

PMID: 36305848 PMC: 10028122. DOI: 10.1002/cam4.5388.

BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer.

Cabarcas-Petroski S, Schramm L Cancers (Basel). 2022; 14(7).

PMID: 35406430 PMC: 8996959. DOI: 10.3390/cancers14071658.

Reply to Schramm, L. Comment on "Li et al. Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. 2021, , 2364".

Li X, Sun L, Stucky A, Tu L, Cai J, Chen X Diagnostics (Basel). 2022; 12(3).

PMID: 35328170 PMC: 8947584. DOI: 10.3390/diagnostics12030617.

Comment on Li et al. Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. 2021, , 2364.

Schramm L Diagnostics (Basel). 2022; 12(3).

PMID: 35328161 PMC: 8947690. DOI: 10.3390/diagnostics12030608.

References

Zhuo Z, Zhou C, Fang Y, Zhu J, Lu H, Zhou H . Correlation between the genetic variants of base excision repair (BER) pathway genes and neuroblastoma susceptibility in eastern Chinese children. Cancer Commun (Lond). 2020; 40(11):641-646. PMC: 7668499. DOI: 10.1002/cac2.12088. View

Schoenen F, Wirth B . The zinc finger protein ZNF297B interacts with BDP1, a subunit of TFIIIB. Biol Chem. 2006; 387(3):277-84. DOI: 10.1515/BC.2006.037. View

Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer R . Targeting anaplastic lymphoma kinase in neuroblastoma. APMIS. 2019; 127(5):288-302. PMC: 6850425. DOI: 10.1111/apm.12940. View

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

London W, Castleberry R, Matthay K, Look A, Seeger R, Shimada H . Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005; 23(27):6459-65. DOI: 10.1200/JCO.2005.05.571. View

Morandi F, Sabatini F, Podesta M, Airoldi I . Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future. Vaccines (Basel). 2021; 9(1). PMC: 7828327. DOI: 10.3390/vaccines9010043. View

Zhuo Z, Lu H, Zhu J, Hua R, Li Y, Yang Z . METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study. Mol Ther Nucleic Acids. 2020; 22:17-26. PMC: 7484523. DOI: 10.1016/j.omtn.2020.08.009. View

Taylor J, Zeki J, Ornell K, Coburn J, Shimada H, Ikegaki N . Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression. J Pediatr Surg. 2019; 54(6):1192-1197. PMC: 6545249. DOI: 10.1016/j.jpedsurg.2019.02.028. View

Li S, Kabeer M . Spatiotemporal switching signals for cancer stem cell activation in pediatric origins of adulthood cancer: Towards a watch-and-wait lifetime strategy for cancer treatment. World J Stem Cells. 2018; 10(2):15-22. PMC: 5840533. DOI: 10.4252/wjsc.v10.i2.15. View

10.

Verma N, Hurlburt A, Wolfe A, Kim M, Kang Y, Kang J . Bdp1 interacts with SNAPc bound to a U6, but not U1, snRNA gene promoter element to establish a stable protein-DNA complex. FEBS Lett. 2018; 592(14):2489-2498. DOI: 10.1002/1873-3468.13169. View

11.

Zhuo Z, Liu W, Zhang J, Zhu J, Zhang R, Tang J . Functional Polymorphisms at ERCC1/XPF Genes Confer Neuroblastoma Risk in Chinese Children. EBioMedicine. 2018; 30:113-119. PMC: 5952228. DOI: 10.1016/j.ebiom.2018.03.003. View

12.

Brady S, Liu Y, Ma X, Gout A, Hagiwara K, Zhou X . Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat Commun. 2020; 11(1):5183. PMC: 7560655. DOI: 10.1038/s41467-020-18987-4. View

13.

Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

14.

Kim M, Tranvo A, Hurlburt A, Verma N, Phan P, Luo J . Assembly of SNAPc, Bdp1, and TBP on the U6 snRNA Gene Promoter in Drosophila melanogaster. Mol Cell Biol. 2020; 40(12). PMC: 7261721. DOI: 10.1128/MCB.00641-19. View

15.

Lee L, Li S . Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective. World J Stem Cells. 2020; 12(8):706-720. PMC: 7477658. DOI: 10.4252/wjsc.v12.i8.706. View

16.

Gouge J, Guthertz N, Kramm K, Dergai O, Abascal-Palacios G, Satia K . Molecular mechanisms of Bdp1 in TFIIIB assembly and RNA polymerase III transcription initiation. Nat Commun. 2017; 8(1):130. PMC: 5526994. DOI: 10.1038/s41467-017-00126-1. View

17.

Son H, Mo H, Yoo N, Lee S . Somatic mutations of cancer-related genes PELP1 and BDP1 in colorectal cancers. Pathol Res Pract. 2020; 216(10):153107. DOI: 10.1016/j.prp.2020.153107. View

18.

Nolan J, Salvucci M, Carberry S, Barat A, Segura M, Fenn J . A Context-Dependent Role for MiR-124-3p on Cell Phenotype, Viability and Chemosensitivity in Neuroblastoma . Front Cell Dev Biol. 2020; 8:559553. PMC: 7714770. DOI: 10.3389/fcell.2020.559553. View

19.

Zhang J, Su Q, Loudon W, Lee K, Luo J, Dethlefs B . Breathing Signature as Vitality Score Index Created by Exercises of Qigong: Implications of Artificial Intelligence Tools Used in Traditional Chinese Medicine. J Funct Morphol Kinesiol. 2019; 4(4). PMC: 6919646. DOI: 10.3390/jfmk4040071. View

20.

Veras I, Rosen E, Schramm L . Inhibition of RNA polymerase III transcription by BRCA1. J Mol Biol. 2009; 387(3):523-31. DOI: 10.1016/j.jmb.2009.02.008. View